Novonesis acquires full control of MicroBioGen to integrate advanced yeast strain capabilities into its bio-solutions portfolio
Executive summary: Novonesis announced the acquisition of the remaining shares of MicroBioGen, achieving full ownership of the Australian yeast technology company. The deal enhances Novonesis’s capabilities in sustainable fermentation by integrating MicroBioGen’s high-yield, non-GMO yeast strains used in biofuel and protein production.
Who is involved: Novonesis (acquirer), MicroBioGen (target), and shareholders of MicroBioGen selling their stake.
Likely next: Completion of regulatory approvals, integration of MicroBioGen’s R&D and production facilities into Novonesis’s bio-solutions division, and potential scaling of yeast-based products in global markets.
Novonesis has agreed to acquire the remaining shares of MicroBioGen, an Australian biotechnology firm specializing in non-GMO yeast strains for sustainable fuel and feed production. The transaction grants Novonesis full ownership of MicroBioGen’s proprietary yeast platform, which includes strains optimized for ethanol and protein production from non-food biomass. This move aligns with Novonesis’s strategy to expand its bio-based solutions in fermentation technology following its 2023 formation from the merger of Novozymes and Chr. Hansen. The deal strengthens Novonesis’s position in the industrial enzymes and microorganisms market, particularly in biofuels and animal nutrition.
Timeline
- — Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities (GlobeNewswire)
Analysis — what this means
Likely next events
- Regulatory filing completion expected by Q4 2026 under Australian foreign investment rules
- Integration of MicroBioGen’s Lark Hill facility into Novonesis Asia-Pacific operations by mid-2027
- Launch of next-gen yeast strain for cellulosic ethanol by Novonesis-MicroBioGen joint team in 2028
Sectors affected
- Industrial enzymes
- Biofuels
- Animal feed additives
- Sustainable fermentation technology
Regulatory implications
- Australian Foreign Acquisition and Takeovers Act 1975 review required for change of control
- No EU antitrust concerns expected due to limited overlap in Novonesis’s existing yeast portfolio
- Potential USDA or EPA engagement if yeast strains are deployed in U.S. biofuel programs
Historical parallels
- Novozymes’ 2012 acquisition of BioResources Ltd. for yeast platform expansion
- DSM’s 2015 buyout of Dyadic International’s yeast strain assets for industrial applications
- Chr. Hansen’s 2018 acquisition of LGG probiotic strain rights to strengthen culture business
Key entities
Sources
Open the full interactive case file on Beyond →